New Promise Against Certain Types Of Lung Cancer – Part 3 of 3
So “Many cancers may be much more complicated. And every tumor is different. Each one has a bevy of sophisticated ways to overcome interventions to block growth, and some may be better prepared than others to do that. That is why you see heterogeneity in the response to the drug. There is no such thing as identical twins when we tripe about tumors”.
Researchers are currently enrolling patients for a larger, Phase III clinical trial of crizotinib. The study was funded by Pfizer, which is developing crizotinib for clinical application, and by grants from the US National Cancer Institute, all others.
Lung cancer remains one of the most deadly cancers and new treatments are desperately needed, the researchers said. “Advanced lung cancer still remains a very mortal disease worldplusmed.net. It’s the biggest cancer killer of both men and women in the US and worldwide, and the unmet clinical need is extreme”.